Johnson Financial Group Inc (Wisconsin)’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-1,400
Closed -$1.74K 777
2023
Q4
$1.74K Hold
1,400
﹤0.01% 757
2023
Q3
$1.6K Buy
+1,400
New +$1.8K ﹤0.01% 605
2022
Q2
Sell
-3,984
Closed -$3K 685
2022
Q1
$3K Buy
+3,984
New +$8.52K ﹤0.01% 628

Other funds holding AKBA

Johnson Financial Group Inc (Wisconsin)'s AKBA Position: Q1 2024 in Review

Johnson Financial Group Inc (Wisconsin) sold out of Akebia Therapeutics (AKBA) in Q1 2024, closing a stake of 1,400 shares — an estimated $1.74K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in AKBA in Q1 2022 and held it in 3 quarters. The position peaked at $3K in Q1 2022. 114 funds tracked by Wall St. Rank hold AKBA as of Q1 2024.

  • Johnson Financial Group Inc (Wisconsin) reported no remaining Akebia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Johnson Financial Group Inc (Wisconsin) sold 1,400 Akebia Therapeutics shares in Q1 2024, an estimated $1.74K.
  • Johnson Financial Group Inc (Wisconsin) first reported a position in Akebia Therapeutics in Q1 2022 and held it in 3 quarters.
  • Johnson Financial Group Inc (Wisconsin)'s Akebia Therapeutics position peaked at $3K in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2024.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q1 2024, filed 14 May 2024.